Literature DB >> 15239874

Is high cord radical orchidectomy always necessary for testicular cancer?

Daniel A Ashdown1, Dhaval Bodiwala, Samson Liu.   

Abstract

BACKGROUND: Radical high cord inguinal orchidectomy remains the standard for diagnosis, staging and treatment of testicular neoplasms. Low cord orchidectomy is an alternative to the high cord orchidectomy.
OBJECTIVE: To test the hypothesis that there is no difference in relapse rate or mortality between high and low cord orchidectomy for the treatment of testicular cancer.
METHODS: A retrospective study was undertaken of all orchidectomies performed for testicular cancer at our hospital between 1981 and 2002.
RESULTS: Overall, 120 high cord orchidectomies and 102 low cord orchidectomies were performed for testicular cancer between 1981 and 2002 at our hospital. Analysis showed that there was no significant difference in the mean age of the patients, the rate of relapse, mean time to relapse or survival between surgical approach for stage 1 tumours. For stage 2-4 tumours, there were not sufficient numbers to comment on the statistical significance of relapse or survival differences.
CONCLUSIONS: The trend suggests that there is no statistically significant difference in the rate of relapse and mortality between high and low cord orchidectomy for clinically stage 1 tumours. We would, therefore, advocate either a high or low cord orchidectomy for clinically stage 1 tumours.

Entities:  

Mesh:

Year:  2004        PMID: 15239874      PMCID: PMC1964202          DOI: 10.1308/147870804272

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  2 in total

Review 1.  Contemporary diagnostic work-up of testicular germ cell tumours.

Authors:  Klaus-Peter Dieckmann; Ulrich Frey; Guntram Lock
Journal:  Nat Rev Urol       Date:  2013-11-12       Impact factor: 14.432

2.  Subinguinal orchiectomy-A minimally invasive approach to open surgery.

Authors:  Elliot Anderson; Claire Pascoe; Niranjan Sathianathen; Darren Katz; Declan Murphy; Nathan Lawrentschuk
Journal:  BJUI Compass       Date:  2020-08-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.